Authors' Reply

J Am Soc Nephrol. 2021 Apr;32(4):1005-1007. doi: 10.1681/ASN.2021010051. Epub 2021 Mar 1.

Authors

Tadao Akizawa¹, Manabu Iwasaki², Yusuke Yamaguchi³, Yoshikatsu Majikawa⁴, Michael Reusch⁵

Affiliations

¹ Department of Nephrology, Showa University School of Medicine, Tokyo, Japan.
² Department of Data Science, Yokohama City University, Yokohama, Japan.
³ Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁴ Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.
⁵ Development Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands.

No abstract available

Keywords: chronic kidney disease; erythropoiesis-stimulating agent; hemodialysis; hypoxia-inducible factor; randomized controlled trial.

Publication types

Letter
Comment